Alzheimers disease (AD), Progressive Supranulcear Palsy (PSP) Alzheimers disease (AD), Progressive Supranulcear Palsy (PSP)
Conditions
Interventions
1. Intravenous injection of radiopharmaceutial such as [18F]SMBT-1 in the right arm and scannning with PET scanner.
2. Insertion of an arterial chatheter into the radiial artery and serial arterial bl
injection of radiopharmaceutial, Insertion of arterial chatheter and serial blood sampling
Sponsors
Tashiro Manabu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Alzheimer's disease (AD) group (1) Informed consent by the participant or by the substitue (native Japanese) (2) Ages: 60 to 85 years old (3) Alzheimer's disease (AD), Progressive Supranulcear Palsy (PSP), Aged normal control (AN) (4) Those who were judged positive in [11C]PiB PET for screening (5) Those who can tolerate relatively long PET examination (up to 2 hours) Progressive Supranulcear Palsy (PSP) group (1) Informed consent by the participant or by the substitue (native Japanese) (2) Ages: 60 to 85 years old (3) Alzheimer's disease (AD), Progressive Supranulcear Palsy (PSP), Aged normal control (AN) (4) Those who were judged negative in [11C]PiB PET for screening (5) Those who can tolerate relatively long PET examination (up to 2 hours) Aged control (AC) group (1) Informed consent by the participant or by the substitue (native Japanese) (2) Ages: basically 60 to 85 years old (If not available, 40 to 60 can be also acceptable) (3) MMSE scores higher than 24 (4) Wechsler memory Scale-R Logical memory II scores higher than cut-off (>3 for those who have education period of 0-7 years; >5 for education period of 8-15 years; >9 for education period of more than 16 years (5) Those who were judged negative in [11C]PiB PET for screening (6) Those who can tolerate relatively long PET examination (up to 2 hours)
Exclusion criteria
Exclusion criteria: AD group and PSP group (1) Other neurological disorders (including cerebrovascular disorders), drug addicts, alcoholism, as well as severe cardiavascular diseases (2) Administration of irreversible MAO-B inhibitors (3) Habitual smoking (including those who have smoked within 1 year) (4) Severe allergic reactions to drugs and foods (including severe ethanol sensitivity) (5) Psychiatric disorders, which may make the participation to this study difficult (6) Taboo conditions for MRI examinations (cardiac pacemaker, intracorpoporial metals, etc. to be checked with questionnaire in advance) (7) Systemic circulatory and metabolic disorders as well as organ dysfuctions, such as diabetes melitus, hypertension, endocrinological disorders, congestive heart failure, angina petoris, severe renal dysfunctions with Ccr<30mL/min or under plasmapheresis) (8) Being diagnosed or treated for malignant diseases within 1 year (9) Any sociomedial conditions, which may make the participation to this study difficult AN group (1) Any neurological disorders (2) drug addicts including alcoholism (3) Habitual smoking (including those who have smoked within 1 year) (4) Severe allergic reactions to drugs and foods (including severe ethanol sensitivity) (5) Psychiatric disorders, which may make the participation to this study difficult (6) Taboo conditions for MRI examinations (cardiac pacemaker, intracorpoporial metals, etc. to be checked with questionnaire in advance) (7) Systemic circulatory and metabolic disorders as well as organ dysfuctions, such as diabetes melitus, hypertension, endocrinological disorders, congestive heart failure, angina petoris, severe renal dysfunctions with Ccr<30mL/min or under plasmapheresis) (8) Being diagnosed or treated for malignant diseases within 1 year (9) Any sociomedial conditions, which may make the participation to this study difficult
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuumulation of [18F]SMBT-1 in the brain regions of AD and PSP patients as well as in ACs such as standardized uptake value (SUV), as well as pharmacokinetic parameters such as K1, k2, k3, k4, binding potential and distribution volume. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Sensitivity and specificity to discriminate AD and PSP patients goups from ACs within this study. Correlations of brain [18F]SMBT-1 accumulation to the cognitive abilities of AD and PSP patients. 2) Correlations between [18F]SMBT-1 accumulation and general cognitive abilities and [11C]PiB. 3) Changes in vital signs (blood pressure, heart rate, SPO2) and blood tests (blood cell counts and blood chemistry) | — |
Contacts
Public ContactKazuko Takeda
Research Center for Accelerator and Radioisotope Science, Tohoku University
Outcome results
None listed